The ICPC represents a component of the NCI cancer moonshot program, with the active participation of more than 20 institutions from 14 countries. The Switzerland ICPC team is currently engaged in two significant Swiss initiatives, namely the Tumor Profiler Project and the Swiss Multiomics Center Project, both of which generate extensive multiomics datasets. The ultimate objective of these endeavors is to facilitate the public accessibility of all multiomic datasets, thereby fostering greater scientific knowledge and advancements in the field of cancer research.
“We are excited to continue our partnership with the Switzerland International Cancer Proteogenome Consortium and work together to advance the field of proteogenomics cancer research,” said Dr. Henry Rodriguez, Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute. “Together, we can accelerate the pace of discovery and ultimately improve patient outcomes.”
The signing of the MOU marks an important step forward in the partnership between the NCI Clinical Proteomic Tumor Analysis Consortium and the Switzerland ICPC team, and has the potential to lead to significant advances in the field of proteogenomics cancer research.
For more information on the NCI Clinical Proteomic Tumor Analysis Consortium, please visit: https://proteomics.cancer.gov/programs/cptac
For more information on the NCI International Cancer Proteogenome Consortium, please visit: https://icpc.cancer.gov
For more information on the Switzerland International Cancer Proteogenome Consortium, please visit: https://www.icpc.ethz.ch
For more information on the Swiss Multi-Omics Center, please visit: http://smoc.ethz.ch/